Your browser doesn't support javascript.
loading
TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
Li, Ke; Wang, Feng; Cao, Wen-Bin; Lv, Xiao-Xi; Hua, Fang; Cui, Bing; Yu, Jiao-Jiao; Zhang, Xiao-Wei; Shang, Shuang; Liu, Shan-Shan; Yu, Jin-Mei; Han, Ming-Zhe; Huang, Bo; Zhang, Ting-Ting; Li, Xia; Jiang, Jian-Dong; Hu, Zhuo-Wei.
Afiliación
  • Li K; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China.
  • Wang F; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China.
  • Cao WB; Hematopoietic Stem Cell Transplantation Center, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, P.R. China.
  • Lv XX; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China.
  • Hua F; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China.
  • Cui B; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China.
  • Yu JJ; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China.
  • Zhang XW; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China.
  • Shang S; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China.
  • Liu SS; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China.
  • Yu JM; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China.
  • Han MZ; Hematopoietic Stem Cell Transplantation Center, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, P.R. China.
  • Huang B; Institute of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, P.R. China.
  • Zhang TT; Department of Pharmacy, Marine College, Shandong University, Weihai 264209, P.R. China.
  • Li X; Department of Pharmacy, Marine College, Shandong University, Weihai 264209, P.R. China.
  • Jiang JD; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China; Institute of Medicinal Biotechnology, Chinese Acad
  • Hu ZW; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China. Electronic address: huzhuowei@imm.ac.cn.
Cancer Cell ; 31(5): 697-710.e7, 2017 05 08.
Article en En | MEDLINE | ID: mdl-28486108
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Proteínas Represoras / Leucemia Promielocítica Aguda / Proteínas de Fusión Oncogénica / Proteína p53 Supresora de Tumor / Senescencia Celular / Proteínas Serina-Treonina Quinasas / Proteínas de Ciclo Celular / Proliferación Celular Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancer Cell Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Proteínas Represoras / Leucemia Promielocítica Aguda / Proteínas de Fusión Oncogénica / Proteína p53 Supresora de Tumor / Senescencia Celular / Proteínas Serina-Treonina Quinasas / Proteínas de Ciclo Celular / Proliferación Celular Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancer Cell Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article